Cabozantinib gains FDA approval for treating advanced neuroendocrine tumors

Cabozantinib gains FDA approval for treating advanced neuroendocrine tumors

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors (NETs).

Center of Excellence Outreach

Can you help us with reaching out to the Centres of Excellence? With your help we will be able to highlight the full range of support and services we offer to the centre of excellence teams and encourage them to inform their patients about our services. Our ask of you: By acting as a ‘bridge’

US FDA approves Exelixis’ Cabometyx for advanced neuroendocrine tumours

The FDA’s approval adds to its five prior approvals and is based on positive outcomes from the CABINET Phase III trial. CABINET is a multicentre, randomised, double-blinded, placebo-controlled The post US FDA approves Exelixis’ Cabometyx for advanced neuroendocrine tumours appeared first on Pharmaceutical Business review.

FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.

Cabozantinib Approved for Unresectable, Advanced/Metastatic epNET and pNET

The FDA approved cabozantinib for use in patients with previously treated unresectable, locally advanced or metastatic, well-differentiated epNETs or pNETs.

FDA Approves Cabozantinib for Advanced Neuroendocrine Tumors

The FDA approved cabozantinib for previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic and extrapancreatic neuroendocrine tumors.